Robert Clancy (doctor)

Last updated

Robert Llewellyn Clancy AM is a retired Australian clinical immunologist in the field of mucosal immunology. He is known for his research and development of therapies for chronic obstructive pulmonary disease (COPD), commonly known as emphysema. [1] [2]

Clancy developed the vaccine Broncostat at the University of Newcastle in 1985. [3]

Clancy is an emeritus professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy. He was previously Foundation Chair of Pathology at the University of Newcastle. Earlier in his career he was the first clinical immunologist at the Royal Prince Alfred Hospital, Sydney. He was educated at North Sydney Boys High School. He holds a BS.Med (Hons) and a MBBS (Hons) from the University of Sydney and a PhD from Monash University. He is a fellow of the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists of Australia (FRCPA). He was admitted as a Member of the Order of Australia (AM, Order of Australia) in 2005 for service to cartography as a collector of early maps of Australia and to the field of immunology. [4]

During the COVID-19 pandemic Clancy was involved in controversy when he was quoted by Australian MP Craig Kelly in support of unverified information about claimed benefits of the drugs hydroxychloroquine and ivermectin. Newcastle University issued a statement in which it distanced itself from Clancy's views, mentioning also that the vice-chancellor had said the university did "not consider Robert Clancy a subject matter expert on COVID-19". [5]

On November 16, 2022 he claimed in "Quadrant" (The Problem with the COVID Narrative) that the medical establishment had ignored the importance of the mucosal immune response to COVID-19 in favour of a high risk focus on stimulating systemic immunity by means of an experimental genetic treatment. [6]

See also

Related Research Articles

Immunostimulants, also known as immunostimulators, are substances that stimulate the immune system usually in a non-specific manner by inducing activation or increasing activity of any of its components. One notable example is the granulocyte macrophage colony-stimulating factor. The goal of this stimulated immune response is usually to help the body have a stronger immune system response in order to improve outcomes in the case of an infection or cancer malignancy. There is also some evidence that immunostimulants may be useful to help decrease severe acute illness related to chronic obstructive pulmonary disease or acute infections in the lungs.

<span class="mw-page-title-main">Ian Frazer</span> Scottish-born Australian immunologist

Ian Hector Frazer is a Scottish-born Australian immunologist, the founding CEO and Director of Research of the Translational Research Institute (Australia). Frazer and Jian Zhou developed and patented the basic technology behind the HPV vaccine against cervical cancer at the University of Queensland. Researchers at the National Cancer Institute, Georgetown University, and University of Rochester also contributed to the further development of the cervical cancer vaccine in parallel.

Christopher Carl Goodnow is an immunology researcher and the current executive director of the Garvan Institute of Medical Research. He holds the Bill and Patricia Ritchie Foundation Chair and is a Conjoint Professor in the faculty of medicine at UNSW Sydney. He holds dual Australian and US citizenship.

<span class="mw-page-title-main">Stefan H. E. Kaufmann</span> German biologist

Stefan Hugo Ernst Kaufmann is a German immunologist and microbiologist and is one of the highly cited immunologists worldwide for the decade 1990 to 2000. He is amongst the 0.01% most cited scientists of c. 7 million scientists in 22 major scientific fields globally.

Francesco Dieli is an Italian immunologist. He was born in Prizzi, Italy. After high school education, in 1983 he got his degree with honors in Medicine at the University of Palermo where he specialized in Pathology. He got his PhD in Immunology in 1999. He is full professor of Immunology and Director of the Division of Immunology and Immunogenetics at the University of Palermo, Italy.

Peter John Morland Openshaw, is a British clinician and scientist specialising in lung immunology, particularly defence against viral infections. He trained in lung diseases and undertook a PhD in immunology before establishing a laboratory at St Mary's Hospital Medical School. He created the academic department of Respiratory Medicine and the Centre for Respiratory Infection at Imperial College and was elected President of the British Society for Immunology in 2014.

<span class="mw-page-title-main">Akiko Iwasaki</span> Immunobiologist

Akiko Iwasaki is a Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University. She is also a principal investigator at the Howard Hughes Medical Institute. Her research interests include innate immunity, autophagy, inflammasomes, sexually transmitted infections, herpes simplex virus, human papillomavirus, respiratory virus infections, influenza infection, T cell immunity, commensal bacteria, COVID-19, and long COVID.

Seung-Yong Seong is a South Korean immunologist and microbiologist known for his study of innate immune system response and his development of the damage-associated molecular pattern (DAMP) model of immune response initiation in collaboration with Polly Matzinger. Seong is also known for his research on the bacterium Orientia tsutsugamushi and his research on immunological adjuvant when he was a student. Since 2013 he has served as Director of the Wide River Institute of Immunology – Seoul National University in conjunction with his Professor position in the Microbiology and Immunology department of Seoul National University College of Medicine. In 2012, he became Editor in Chief of the World Journal of Immunology.

Jean Sylvia Marshall, born in Birmingham, England, is a Canadian immunologist and acting Professor and Head of the Department of Microbiology & Immunology at Dalhousie University in Halifax, Nova Scotia, Canada. Marshall's work has investigated how mast cells are involved in the early immune response to infection and antigen. She is best known for her discovery of the previously unknown degranulation-independent immunoregulatory roles of mast cells in infection and allergy and their ability to mobilize dendritic cells.

Dr. Joanna Groom is an Australian Immunologist and Laboratory Head in the Immunology Division at the Walter and Eliza Hall Institute and WEHI CSL Centenary fellow. Her research focuses on how the communication and positioning of immune cells influences the immune response using 3D imaging methods with transcriptional analysis.

<span class="mw-page-title-main">Graham Le Gros</span> New Zealand immunologist

Graham Stephen Le Gros is a New Zealand immunologist. He is currently Director of the Malaghan Institute of Medical Research in Wellington, New Zealand and leads its Allergic and Parasitic Diseases Programme. He is also Research Director of the Vaccine Alliance Aotearoa New Zealand – Ohu Kaupare Huaketo and a Research Professor at Victoria University of Wellington.

Michael Joseph Mina is an American epidemiologist, immunologist and physician. He was formerly an assistant professor of Epidemiology & Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health, assistant Professor of Pathology at Brigham and Women's Hospital, Harvard Medical School, and currently Chief Medical Officer at eMed.

Emeritus Professor Maree Gleeson is an Australian immunologist. Her research has focused on respiratory immunology in children and elite athletes. She has held multiple leadership positions within the health sector in the Hunter Region in NSW.

<span class="mw-page-title-main">Daniela M. Ferreira</span> Brazilian immunologist

Daniela M. Ferreira is a Brazilian British immunologist. She is a specialist in bacterial infection, respiratory co-infection, mucosal immunology and vaccine responses. She is currently Professor of Respiratory Infection and Vaccinology at the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford and the Director of the Liverpool Vaccine Group at the Liverpool School of Tropical Medicine. She leads a team of scientists studying protective immune responses against pneumococcus and other respiratory pathogens such as SARS-CoV2. Her team has established a novel method of inducing pneumococcal carriage in human volunteers. They use this model to:

<span class="mw-page-title-main">Alessandra Pucci</span> Australian biochemist and entrepreneur

Alessandra Alberta Pucci is an Australian immunologist and entrepreneur who founded and led Australian Monoclonal Development, the first biotechnology company in Australia.

Jan Roland Holmgren is a Swedish physician, microbiologist, immunologist, and vaccinologist, known for his research on cholera and mucosal immunology, specifically, for his leadership in developing "the world's first effective oral cholera vaccine".

Graeme John Stewart,, MB BS, PhD, FRACP, FRCPA is an Australian consultant physician, medical researcher in the field of immunology, and a community health advocate. He is Clinical Professor of Medicine in the Westmead Institute for Medical Research, University of Sydney.

<span class="mw-page-title-main">De'Broski R. Herbert</span> American immunologist

De’Broski. R. Herbert is an immunologist, parasitologist, academic, and biomedical researcher. He ẁas appointed Professor of Immunology in 2021, and Penn Presidential Professor at the University of Pennsylvania School of Veterinary Medicine. He is also the Associate Director for Institute of Infectious and Zoonotic Disease (PennVet), and an affiliated Scientist at the Monell Chemical Senses Center.

Jennifer Lynn Gommerman is a Canadian immunologist. She is a Tier 1 Canada Research Chair in Tissue-Specific Immunity at the University of Toronto. Gommerman has been examining the role of B lymphocytes in Multiple Sclerosis patients and in animal models of MS. She also studies the antibody response to SARS-CoV-2 in saliva samples from patients with COVID-19.

<span class="mw-page-title-main">Nimesh Gupta</span> Virologist and Immunologist

Dr. Nimesh Gupta, an Indian vaccine immunologist, is a senior scientist and the Chief of the Vaccine Immunology Laboratory at the National Institute of Immunology in India. He has done research on understanding the T-cell determinants of long-term and broadly protective immunity against virus infection and vaccination. In addition to his research, Dr. Gupta has established a Human Immune Monitoring and T-cell Assay Platform for vaccine evaluation.

References

  1. Clancy, RL (2012). "Towards a vaccine for chronic obstructive pulmonary disease". Intern Med J. 42 (6): 607–13. doi:10.1111/j.1445-5994.2012.02752.x. PMID   22372964. S2CID   10937124.
  2. ABC Classic FM, Mornings with Margaret Throsby, Interview with Emeritus Professor Robert Clancy, Tuesday 30 March 2010, http://www.abc.net.au/classic/throsby/stories/s2856046.htm
  3. "Biotechnology Innovation". biotechnology-innovation.com.au. Archived from the original on 19 July 2008.
  4. "It's an Honour - Honours - Search Australian Honours". www.itsanhonour.gov.au.
  5. Parris, Michael (3 February 2021). "Vice-chancellor Alex Zelinsky says Newcastle University professor backing Liberal MP Craig Kelly's COVID-19 claims 'not an expert'". Newcastle Herald.
  6. https://quadrant.org.au/opinion/covidiocy/2022/11/the-problem-with-the-covid-narrative/